- Home
- PBFS vs TNGX Comparison
PBFS vs TNGX Comparison
Compare PBFS & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBFS
- TNGX
- Stock Information
- Founded
- PBFS 1889
- TNGX 2014
- Country
- PBFS United States
- TNGX United States
- Employees
- PBFS N/A
- TNGX N/A
- Industry
- PBFS Banks
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- PBFS Finance
- TNGX Health Care
- Exchange
- PBFS Nasdaq
- TNGX Nasdaq
- Market Cap
- PBFS 309.6M
- TNGX 317.4M
- IPO Year
- PBFS N/A
- TNGX N/A
- Fundamental
- Price
- PBFS $11.68
- TNGX $1.76
- Analyst Decision
- PBFS
- TNGX Strong Buy
- Analyst Count
- PBFS 0
- TNGX 7
- Target Price
- PBFS N/A
- TNGX $12.33
- AVG Volume (30 Days)
- PBFS 26.6K
- TNGX 801.9K
- Earning Date
- PBFS 05-12-2025
- TNGX 05-07-2025
- Dividend Yield
- PBFS N/A
- TNGX N/A
- EPS Growth
- PBFS 11.77
- TNGX N/A
- EPS
- PBFS 0.76
- TNGX N/A
- Revenue
- PBFS $88,118,000.00
- TNGX $42,069,000.00
- Revenue This Year
- PBFS N/A
- TNGX N/A
- Revenue Next Year
- PBFS N/A
- TNGX N/A
- P/E Ratio
- PBFS $15.61
- TNGX N/A
- Revenue Growth
- PBFS 21.67
- TNGX 15.17
- 52 Week Low
- PBFS $8.76
- TNGX $1.71
- 52 Week High
- PBFS $12.20
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- PBFS 44.64
- TNGX 33.97
- Support Level
- PBFS $11.76
- TNGX $1.80
- Resistance Level
- PBFS $12.04
- TNGX $2.04
- Average True Range (ATR)
- PBFS 0.25
- TNGX 0.18
- MACD
- PBFS -0.02
- TNGX 0.01
- Stochastic Oscillator
- PBFS 11.86
- TNGX 20.19
About PBFS Pioneer Bancorp Inc.
Pioneer Bancorp Inc is involved in providing banking services. These services include Personal services such as Checking, Savings, eBanking Cards, and Business services such as Business Deposit and operating Accounts, Business eBanking, and Business loans. Some of the other services of the company include Government Banking, Wealth Management, Benefits Consulting and Insurance.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.